Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Sponsor: Vir Biotechnology, Inc.
Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Official title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2020-07-03
Completion Date
2024-03-25
Last Updated
2026-04-16
Healthy Volunteers
No
Conditions
Interventions
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Locations (22)
Investigative Site
Birtinya, Queensland, Australia
Investigative Site
Fitzroy, Victoria, Australia
Investigative site
Hong Kong, Hong Kong
Investigative Site
Batu Caves, Malaysia
Investigative Site
Kajang, Malaysia
Investigative Site
Kuala Lumpur, Malaysia
Investigative Site
Kuantan, Malaysia
Investigative Site
Auckland, New Zealand
Investigative Site
Auckland, New Zealand
Investigative Site
Busan, South Korea
Investigative Site
Chuncheon, South Korea
Investigative Site
Daegu, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Yangsan, South Korea
Investigative Site
Bangkok, Thailand
Investigative Site
Bangkok, Thailand
Investigative Site
Bangkok, Thailand
Investigative Site
Chiang Mai, Thailand
Investigative Site
Hat Yai, Thailand
Investigative Site
Khlong Luang, Thailand
Investigative Site
Khon Kaen, Thailand